Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.
Original Article: Myriad Genetics announces new data on EndoPredict test at 2017 San Antonio Breast Cancer Symposium
NEXT ARTICLE